S2209, A Phase III Randomized Trial For Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail Or In A Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance
Lay Description
To compare progression-free survival (PFS) in frail or selected intermediate fit Newly Diagnosed Multiple Myeloma (NDMM) participants treated with VRd-Lite induction followed by Lenalidomide maintenance (Arm 1) versus DRd induction followed by Lenalidomide maintenance (Arm 2).
To compare overall survival (OS) in frail or selected intermediate fit NDMM participants treated with VRd-Lite induction followed by lenalidomide maintenance (Arm 1) versus DRd induction followed by lenalidomide and daratumumab and hyaluronidase-fihj maintenance (Arm 3).
Category
- Cancers and Other Neoplasms
- Myeloma
- IRB Number
- STUDY00000140
- NCT Number
- NCT # not yet entered
Eligibility
- Eligible Ages
- 18 and over
- Eligible Genders
- ALL
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Frances Crawford
210-450-5037
crawfordf1@uthscsa.edu
Myrna Montenegro
210-450-5954
montenegro@uthscsa.edu
Kathleen Rodriguez
210-450-1365
rodriguezk3@uthscsa.edu
Benjamin Schleif
210-450-1366
schleifb@uthscsa.edu
Morgan Seekatz
210-450-1133
seekatz@uthscsa.edu
Jessica Villarreal
villarreal24@uthscsa.edu
Principal Investigator
Matthew Butler